A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel

First-line chemotherapy for men with metastatic castration-resistant prostate cancer (mCRPC) has been employed to improve overall survival (OS) and progression-free survival (PFS). However, several new agents for CRPC after first-line chemotherapy prolonged survival by only a few months. To develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Masanori, Fujimoto, Kiyohide, Arai, Gaku, Uemura, Hiroji, Hashine, Katsuyoshi, Matsumoto, Hiroaki, Fukasawa, Satoshi, Kohjimoto, Yasuo, Nakatsu, Hideomi, Takenaka, Atsushi, Fujisawa, Masato, Uemura, Hirotsugu, Naito, Seiji, Egawa, Shin, Fujimoto, Hiroyuki, Hinotsu, Shiro, Itoh, Kyogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709822/
https://www.ncbi.nlm.nih.gov/pubmed/33200227
http://dx.doi.org/10.3892/or.2020.7847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709822/
https://www.ncbi.nlm.nih.gov/pubmed/33200227
http://dx.doi.org/10.3892/or.2020.7847

Ejemplares similares